Toshiba Medical Systems Corp. and advaced visualization software maker Vital Images Inc. announced they have entered into a definitive merger agreement.
May 2, 2011 – The mid-point for enrollment was reached in of the international APPOSITION III study of Stentys self-apposing coronary stent. About 250 patients are now enrolled out of a total of 500. The trial primary endpoint is major adverse cardiac events (MACE) at 12 months post-procedure.
Death rates are similar at one year for a catheter-based aortic valve replacement procedure and conventional surgery in ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The RIVAL Trial, the largest randomized trial to compare radial access and femoral access for coronary angiography and ...
www.Womenheart.org is the only national organization dedicated to promoting women's heart health through advocacy ...
April 26, 2011 – The U.S. Food and Drug Administration (FDA) announced this week it cleared Boston Scientific’s Ion paclitaxel-eluting coronary stent system. The stent, available for use with monorail or over-the-wire delivery systems, is made of platinum chromium (PtCr) alloy designed specifically for coronary stenting and intended to improve the acute performance of coronary stent implantation in the treatment of coronary artery disease. The stent’s alloy and design offer greater strength, enhanced deliverability and exceptional visibility. The thin-strut stent is designed for improved conformability, minimal recoil, and uniform lesion coverage and drug distribution
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
April 22, 2011 – The first patient has been treated in a European multicenter CIRCUS trial. The study is looking at NeuroVive Pharmaceutical’s CicloMulsion cremophor-free IV cyclosporine formulation in 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction.
April 22, 2011 – At the Society of Nuclear Medicine’s annual meeting, Philips will highlight several new imaging systems. The meeting will take place June 4-8 in San Antonio, Texas.
April 22, 2011 – The American Diabetes Association (ADA) has invited NewCardio to present the results of a key study of the company’s urgent care solution, my3KG. Results showed that the solution had substantially greater accuracy than expert cardiologists' interpretation of standard 12-lead ECG (12L ECG) in diagnosing acute myocardial infarction (AMI) in diabetic patients.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
April 22, 2011 – A new study found that coronary artery bypass surgery added to medical therapy for selected chronic heart failure patients offered benefits over medical therapy alone.
April 22, 2011 – The U.S. Food and Drug Administration (FDA) has cleared the Trifecta valve, by St. Jude Medical. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart.
April 22, 2011 – The Society of Interventional Radiology (SIR) has a long-term commitment to radiation safety, taking a leading role in measuring and assessing radiation dosage; developing educational programs on radiation safety, radiation protection and reduction of skin dosage; and promoting the safety of patients and healthcare professionals.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
April 21, 2011 – A new intravascular ultrasound (IVUS) coronary imaging system has received the CE Mark. With the approval, the LipiScan IVUS system, from InfraReDx, is available for the detection of the plaques known to complicate stenting and believed to be the reason for most heart attacks.
April 21, 2011 – ScImage announced the launch of a project to assist the United States Air Force (USAF), Aeromedical Consultation Service (ACS) with the collection, assessment and reporting tools necessary to expedite cardiovascular decisions for rated aviators, while concurrently reducing flight disqualification delays.
April 21, 2011 – A new angiotensin II receptor blocker (ARB) has been approved by the U.S. Food and Drug Administration (FDA) to treat hypertension, or high blood pressure. Edarbi (azilsartan medoxomil), by Takeda Pharmaceutical Company, is now available by prescription for adults in U.S. pharmacies.